These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 27450690)

  • 1. Introduction: Cancer Immunology Special Issue-Immunopathology.
    Kawakami Y
    Int Immunol; 2016 Aug; 28(8):371. PubMed ID: 27450690
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting neoantigens to augment antitumour immunity.
    Yarchoan M; Johnson BA; Lutz ER; Laheru DA; Jaffee EM
    Nat Rev Cancer; 2017 Apr; 17(4):209-222. PubMed ID: 28233802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation.
    Yaguchi T; Kawakami Y
    Int Immunol; 2016 Aug; 28(8):393-9. PubMed ID: 27401477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Introduction: Cancer Immunology Special Issue-Immunotherapy.
    Kawakami Y
    Int Immunol; 2016 Jul; 28(7):317. PubMed ID: 27313100
    [No Abstract]   [Full Text] [Related]  

  • 5. Editorial: international reviews of immunology.
    Internati MC; Mirandola L; Bot A
    Int Rev Immunol; 2014 Oct; 33(5):365-6. PubMed ID: 25277338
    [No Abstract]   [Full Text] [Related]  

  • 6. Introduction to checkpoint inhibitors and cancer immunotherapy.
    Sharpe AH
    Immunol Rev; 2017 Mar; 276(1):5-8. PubMed ID: 28258698
    [No Abstract]   [Full Text] [Related]  

  • 7. CANCER IMMUNOLOGY. The "cancer immunogram".
    Blank CU; Haanen JB; Ribas A; Schumacher TN
    Science; 2016 May; 352(6286):658-60. PubMed ID: 27151852
    [No Abstract]   [Full Text] [Related]  

  • 8. [Technological advances in immuno-oncology: from fundamental concepts to patient immunological monitoring].
    Chouaib S; Echchakir H; Angevin E; Guerra N; Kosmatopoulos K; Caignard A; Lim A; Baron V; Ferradini L; Mami-Chouaib F
    Bull Cancer; 2001 Aug; 88(8):733-40. PubMed ID: 11578941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Identification of human tumor antigens recognized by T cells].
    Kawakami Y
    Nihon Rinsho; 2005 Apr; 63 Suppl 4():562-7. PubMed ID: 15861711
    [No Abstract]   [Full Text] [Related]  

  • 10. [Molecular targets for development of cancer immunotherapy].
    Kawakami Y
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():144-8. PubMed ID: 23513828
    [No Abstract]   [Full Text] [Related]  

  • 11. Tackling Resistance to Cancer Immunotherapy: What Do We Know?
    Gondhowiardjo SA; Handoko ; Jayalie VF; Apriantoni R; Barata AR; Senoaji F; Utami IJW; Maubere F; Nuryadi E; Giselvania A
    Molecules; 2020 Sep; 25(18):. PubMed ID: 32911646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The T-cell-inflamed tumor microenvironment as a paradigm for immunotherapy drug development.
    Olson DJ; Luke JJ
    Immunotherapy; 2019 Feb; 11(3):155-159. PubMed ID: 30730272
    [No Abstract]   [Full Text] [Related]  

  • 13. Whole tumor cell vaccines for glioma immunotherapy.
    Field CS; Hermans IF; Hunn MK
    Immunotherapy; 2016; 8(4):387-9. PubMed ID: 26973119
    [No Abstract]   [Full Text] [Related]  

  • 14. [Molecular bases of cancer immunology].
    Barrera-Rodríguez R; Peralta-Zaragoza O; Madrid-Marina V
    Salud Publica Mex; 1995; 37(4):344-53. PubMed ID: 7502157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Links between genetics and immunology: mutations and antigens.
    Ayyoub M
    Bull Acad Natl Med; 2016 Jan; 200(1):67-79. PubMed ID: 29889414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement as a Biological Tool to Control Tumor Growth.
    Macor P; Capolla S; Tedesco F
    Front Immunol; 2018; 9():2203. PubMed ID: 30319647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiation-enhanced immune response to cancer: workshop, Anaheim, CA, April 17, 2005.
    Sutherland RM
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):3-5. PubMed ID: 16377408
    [No Abstract]   [Full Text] [Related]  

  • 18. Tumour escape from the immune response: the last hurdle for successful immunotherapy of cancer?
    Pawelec G
    Cancer Immunol Immunother; 1999 Oct; 48(7):343-5. PubMed ID: 10501845
    [No Abstract]   [Full Text] [Related]  

  • 19. Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade?
    Furness AJ; Quezada SA; Peggs KS
    Immunotherapy; 2016 Jun; 8(7):763-6. PubMed ID: 27349975
    [No Abstract]   [Full Text] [Related]  

  • 20. The Summit for Cancer Immunotherapy (Summit4CI), June 26-29, 2016 Halifax, Canada.
    Wouters MCA; Laumont CM; Chen B; Han SJ; Matuszewska K; Potts K; Boudreau JE; Krawczyk CM
    Cancer Immunol Immunother; 2017 Jun; 66(6):811-818. PubMed ID: 28409191
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.